A Daily Network publication
Explore the network
Secondaries Daily
The Daily Read on the Secondary Market
Thursday, September 24, 2026The Morning Brief →Sign in
The MomentumThe Wrap

The $101 million print cannot mark an unpriced continuation vehicle

A bank's balance-sheet sale is not an asset mark, and the week's three unpriced continuation vehicles show the GP-led market still has no external anchor.

The secondaries market produced one number this week: $101 million, the size of a bank position that traded, which the week's coverage treated as the LP-led side's anchor and the external reference a buyer could carry into a negotiation over Amulet's unpriced US Fertility continuation vehicle. That is a lot of interpretive weight for a single balance-sheet decision, and the same reporting handed over the reason it cannot bear it.

The week's coverage found banks and pensions restocking LP-led supply, and sellers of that kind price off the balance sheet rather than the asset; read that once more, because it sorts the parties cleanly. A bank selling a private equity position is transacting relief — capital treatment, liquidity, an exposure that stops consuming balance-sheet capacity the moment it leaves. The cash that clears such a trade reflects the seller's calendar and constraint as much as the fund's prospects, which makes the number a serviceable comp for other constrained sellers and for very little else.

The week's second reference arrived from the same corner: a BlackRock agreement with a Dutch pension fund supplied the other piece of LP-led flow the reporting identified, and a pension fund working against funding rules and a liquidity calendar is not a voluntary seller forming a view on the next three years of a portfolio. Its price, like the bank's, answers a question about the owner.

BDO's research, reported this week, explains why the rest of the LP-led market is quiet rather than cheap. A longer tail of funds running past five years has swollen the supply of positions LPs might sell, while sponsors told the surveyors they expect to buy at higher prices; voluntary sellers, unwilling to trade below marks, wait. That pairing points to books that will price slowly rather than cheaply, which means the paper that does print belongs to owners with a reason to sell that has nothing to do with the mark on the fund. The tape is a census of the motivated, and it is being read all week as though it were a survey of the market.

The tape is a census of the motivated, and it is being read all week as though it were a survey of the market.

What a bank is actually selling

The two sides price against different things: an LP-led buyer underwrites a portfolio against reported marks and a discount, so the NAV on the seller's books is the reference point, contested by a spread; a lead buyer in a GP-led process underwrites a single asset against a mark the sponsor sets, and the week's coverage described StepStone's fertility vehicle as pricing equity like credit rather than off the tape. That description suggests terms are carrying what a market reference would otherwise carry, and if that is the mechanism, the GP-led price is a negotiated number with a sponsor's valuation underneath it, which a bank's capital decision cannot substitute for.

The week's framing of two pricing regimes, one anchored and one not, is generous to the LP-led side of it; there is one regime, and it prices in private. What the bank trade genuinely establishes is that a bid exists for institutional supply, real information about this market's capacity to absorb size. What it does not establish is what a portfolio of funds is worth, and a buyer who carries the $101 million into a continuation vehicle negotiation is marking a sponsor's asset with a regulated seller's relief — the fact that it is the only print of the week does not make it the right one.

Three closings, no marks

Amulet closed its US Fertility continuation vehicle with no reported price on September 18, and four days later Certares and New 2ND Capital closed Guardian Alarm's security-services vehicle also without a published mark, giving the week three GP-led closings on those terms; sponsor valuations, it concluded, now set the price whether the asset is a fertility business or a security-services one.

That is a different underwriting problem from the one the LP-led market poses: a buyer of an LP interest can argue with a discount, because the mark across the table is at least an attempt at a shared language, while a buyer in a GP-led process argues with the sponsor's own number, and the gap between what gets published and what gets agreed is where the price lives. Three closings and no marks in a week is a market discovering price deal by deal, with each result staying in the room.

The coverage put a word to the pattern: benchmark-free pricing is the default now, not a concession extracted in a difficult market, and three closings without a published mark in a single week is what a default looks like in practice. That changes what a buyer is being asked to do: a benchmark is not decoration in these negotiations; it caps the spread a seller can hold for, and it gives an LP deciding whether to roll or take the exit a second opinion. Remove it and the decision rests on the sponsor's valuation and the buyer's willingness to accept it, a test of confidence rather than of price.

The audience for those results is widening: the week's coverage noted that the continuation vehicle, built to hand LPs an exit, has become a front door for small LPs, with their OCIOs possibly through it first. An investor who arrives that way has no seat at the pricing negotiation and no public comp to test the outcome against, which turns the missing benchmark from a curiosity into a cost.

The print that would price a CV

The number that would benchmark Amulet's fertility vehicle and Guardian Alarm's security-services vehicle has not printed; it would look like a voluntary LP-led portfolio sold at a fund-level price, a diversified book offered by an owner with the option to hold and cleared at a mark someone outside the room can see. Nothing in the week's reporting is that trade, and the absence is what keeps a rising count of GP-led closings from producing a price anyone can use.

The absence also explains why sponsor optimism survives: with no voluntary LP-led book printing at a visible price, there is no public number against which a sponsor's mark looks aggressive, and the BDO respondents who expect to buy at higher prices are negotiating in a market that has not yet told them otherwise. An empty comp is not support for a valuation, but in a room where only one party brought a mark, it works the same way.

Buyers in the week's unpriced deals are therefore underwriting a sponsor's valuation, and whatever structure they negotiate is doing the work a market comp would otherwise do. That is a defensible trade while the LP-led market stays stalled, and BDO's finding — sponsors expecting higher prices, voluntary sellers refusing to sell below marks — gives no reason to think it unstalls soon. It is also a trade with a condition attached: let a voluntary LP-led book clear at a visible discount to its marks, and the continuation vehicles closed this week acquire a benchmark no sponsor set, at which point the terms that felt like compensation start to look like the price of not knowing.

BDO's pair of positions is what to watch. Supply stacked with funds past five years argues that the seller's side gives first; if it does, the first voluntary LP-led portfolio to clear at a fund-level price will mark everything that closed this week without one, fertility businesses and security services alike, and it will do so for reasons that have nothing to do with a bank's capital ratio.

More from Secondaries Daily
The Wrap

A $101 million print forces the CV debate

Priced LP-led trades give buyers a benchmark to use against Amulet's unpriced US Fertility continuation vehicle.
The Wrap

Two secondary pricing regimes, and only one has an anchor

A $101 million bank position and a Dutch pension fund set one reference for the week's LP-led supply; Amulet's US Fertility continuation vehicle closes with no published price, leaving buyers to run two underwriting models.
The Wrap

GP stakes clear the secondaries backlog

A $4.7 billion Orix–Anchorage Capital closing shows capital moving through manager economics while LP-led trades stay stalled.
Elsewhere in the networkAll titles →
Every weekday · 6:30 a.m. ET

The Morning Brief

The private wealth industry in four minutes, every weekday at 6:30 a.m. ET. Free.